Literature DB >> 22798751

Review.

Chandrajit P Raut1.   

Abstract

Year:  2008        PMID： 22798751      PMCID： PMC3394479     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  12 in total

1.  Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis of c-kit.

Authors:  A E Rader; A Avery; C L Wait; L S McGreevey; D Faigel; M C Heinrich
Journal:  Cancer       Date:  2001-08-25       Impact factor: 6.860

2.  A case and literature review of complicated gastrointestinal stromal tumors.

Authors:  Santosh S Kale; Mankanwal S Sachdev; Mohammad K Ismail; Rene Davila; Claudio R Tombazzi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-09

Review 3.  Gastrointestinal stromal tumors: pathology and prognosis at different sites.

Authors:  Markku Miettinen; Jerzy Lasota
Journal:  Semin Diagn Pathol       Date:  2006-05       Impact factor: 3.464

4.  Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.

Authors:  S Bonvalot; H Eldweny; C Le Péchoux; D Vanel; P Terrier; A Cavalcanti; C Robert; N Lassau; A Le Cesne
Journal:  Ann Surg Oncol       Date:  2006-12       Impact factor: 5.344

5.  Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

Authors:  Alessandro Gronchi; Marco Fiore; Francesca Miselli; Maria Stefania Lagonigro; Paola Coco; Antonella Messina; Silvana Pilotti; Paolo Giovanni Casali
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

6.  Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.

Authors:  Chandrajit P Raut; Matthew Posner; Jayesh Desai; Jeffrey A Morgan; Suzanne George; David Zahrieh; Christopher D M Fletcher; George D Demetri; Monica M Bertagnolli
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

7.  Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.

Authors:  Bengt Nilsson; Per Bümming; Jeanne M Meis-Kindblom; Anders Odén; Aydin Dortok; Bengt Gustavsson; Katarzyna Sablinska; Lars-Gunnar Kindblom
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

8.  Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.

Authors:  Robert H I Andtbacka; Chaan S Ng; Courtney L Scaife; Janice N Cormier; Kelly K Hunt; Peter W T Pisters; Raphael E Pollock; Robert S Benjamin; Michael A Burgess; Lei L Chen; Jonathan Trent; Shreyaskumar R Patel; Kevin Raymond; Barry W Feig
Journal:  Ann Surg Oncol       Date:  2007-01       Impact factor: 5.344

9.  Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.

Authors:  Piotr Rutkowski; Zbigniew Nowecki; Pawel Nyckowski; Wirginiusz Dziewirski; Urszula Grzesiakowska; Anna Nasierowska-Guttmejer; Marek Krawczyk; Wlodzimierz Ruka
Journal:  J Surg Oncol       Date:  2006-03-15       Impact factor: 3.454

Review 10.  NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

Authors:  George D Demetri; Robert S Benjamin; Charles D Blanke; Jean-Yves Blay; Paolo Casali; Haesun Choi; Christopher L Corless; Maria Debiec-Rychter; Ronald P DeMatteo; David S Ettinger; George A Fisher; Christopher D M Fletcher; Alessandro Gronchi; Peter Hohenberger; Miranda Hughes; Heikki Joensuu; Ian Judson; Axel Le Cesne; Robert G Maki; Michael Morse; Alberto S Pappo; Peter W T Pisters; Chandrajit P Raut; Peter Reichardt; Douglas S Tyler; Annick D Van den Abbeele; Margaret von Mehren; Jeffrey D Wayne; John Zalcberg
Journal:  J Natl Compr Canc Netw       Date:  2007-07       Impact factor: 11.908
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.